Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03812393 2023-12-18

FACT-2

Phase 2 Unknown

27 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04781374 2023-07-11

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02673398 2023-06-18

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

Phase 2 Completed

25 enrolled 18 charts

Breast

HER2 Positive Breast Carcinoma

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast

Breast Neoplasms

NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Completed

49 enrolled 17 charts

Breast

Breast Neoplasms

NCT04460430 2022-10-25

NEREA

Phase 2 Terminated

12 enrolled

Breast

Breast Neoplasms

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Not yet recruiting

500 enrolled

Breast

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2 Completed

563 enrolled 16 charts

Breast

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Phase 2 Completed

56 enrolled 29 charts

Breast

Breast Neoplasms

NCT03457896 2022-03-31

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2 Unknown

35 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

Clinical Trials

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

I-SPY

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

INTUITT-NF2

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

THUNDER

ELEANOR

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

iNNOVATE

SAFIR-ABC10

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

DIANER

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Using Tumor Models to Determine Treatments

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

NeraHER2

SPRING

CVL009-C2001

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

SUMMIT

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

FACT-2

HER2-Signal

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NEREA

Treatment Patterns of Neratinib in HER2+ EBC in China

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NeraBrain